StockNow
CalendarLog in
U.S. Markets

Abbvie (ABBV) says that Apogee's global Phase 3 atopic dermatitis program is seen to begin enrollment in 2026, targeting an early-2030 launch

StockNow breaking-news AI analysis

AbbVie plans to start Phase 3 enrollment for Apogee's atopic dermatitis candidate zumilokibart in 2026, aiming for an early-2030 launch to compete against Dupixent.

2 stocks
ABBVABBVIE INC.$261.46Current priceAPGEApogee Therapeutics, Inc. Common Stock$135.10Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Economy

US ADP Employment Change Weekly 16.25K (Prev. 12K)

Politics

Libya's NOC says production and operations have been suspended in 3 oil fields after a valve was closed on the Al-Hamada-Zawiya pipeline, may need to declare force majeure if its remains closed

Commodities

Saudi Arabia is reportedly informing some European oil refiners that their Sep' loading of crude cargoes are cancelled, according to sources